The Open Nuclear Medicine Journal
2013, 5 : 1-4Published online 2013 July 12. DOI: 10.2174/1876388X01305010001
Publisher ID: TONMEDJ-5-1
I-Vascular Endothelial Growth Factor-165 (I-VEGF) Scintigraphy for Visualisation of Extranodal Marginal Zone B-Cell Lymphoma of the Mucosa-Associated Lymphoid Tissue (MALT) Type
ABSTRACT
Aim:
Vascular endothelial growth factor (VEGF) and VEGF receptor are over-expressed in lymphomagenesis. The aim of this study was to evaluate the usefulness of 123I-VEGF165 scintigraphy for imaging of B-cell lymphoma of the Mucosa-Associated Lymphoid Tissue (MALT lymphoma).
Methods:
Three Patients (age range: 52-71 years) with histopathological verified MALT lymphoma were included in the study. Two patients had disseminated MALT-lymphoma and one patient had parotid MALT-lymphoma with involvement of cervical lymph nodes. Recombinant VEGF165 was radiolabeled with 123I by electrophilic radioiodination using the chloramine T method. Each patient received 172 MBq (<130 pmole (< 5 μg) VEGF165 per patient) of 123I-VEGF165. Dynamic acquisition was initiated immediately after administration and carried out until 30 minutes post injection. Whole-body images were acquired in anterior and posterior views at various times points post injection (p.i.). SPECT was performed 1 hour p.i.
Results:
None of the patients with MALT lymphoma showed pathologically increased focal 123I-VEGF uptake in verified tumor lesions. No clinical adverse reaction and no side-effects after intravenous application of 123I-VEGF165 were found.
Results:
None of the patients with MALT lymphoma showed pathologically increased focal 123I-VEGF uptake in verified tumor lesions. No clinical adverse reaction and no side-effects after intravenous application of 123I-VEGF165 were found.
Conclusions:
Our results suggest that 123I-VEGF165 scintigraphy does not visualize B-cell lymphomas of MALT type.